VYNE Therapeutics (VYNE) Change in Acquisitions & Divestments (2017 - 2026)

VYNE Therapeutics' Change in Acquisitions & Divestments history runs 8 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 86.01% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.4 million (down 28.82% YoY) and the FY2025 annual result came in at $68.3 million, down 18.69% from the prior year.
• Change in Acquisitions & Divestments was $4.7 million for Q1 2026 at VYNE Therapeutics, down from $14.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $33.6 million in Q1 2025 and bottomed at $4.7 million in Q1 2026.
• A 3-year average of $19.5 million and a median of $22.9 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments surged 189.66% — and 2026, when it tumbled 86.01%.
• VYNE Therapeutics' Change in Acquisitions & Divestments stood at $22.9 million in 2024, then sank by 37.77% to $14.2 million in 2025, then slumped by 67.02% to $4.7 million in 2026.
• Business Quant data shows VYNE's Change in Acquisitions & Divestments at $4.7 million in Q1 2026, $14.2 million in Q2 2025, and $33.6 million in Q1 2025.